Skip to main content

Table 4 Immune reconstitution within 1 year post-transplantation (absolute value)

From: Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial

   CD3+ CD3+CD4+ CD3+CD8+ CD19+ CD3-CD56+
Months after allo-HSCT   Mean absolute value (109/L, range) Mean absolute value (109/L, range) Mean absolute value (109/L, range) Mean absolute value (109/L, range) Mean absolute value (109/L, range)
1st(N=202) Sorafenib group 0.450 (0.025–1.218) 0.086 (0.0070.239) 0.296 (0.0090.938) 0.009 (0.0000.049) 0.137 (0.0240.336)
Control group 0.621 (0.0471.515) 0.085 (0.0070.144) 0.451 (0.0321.392) 0.010 (0.0010.035) 0.193 (0.0790.378)
P 0.267 0.966 0.262 0.870 0.159
3rd(N=188) Sorafenib group 0.985 (0.1912.835) 0.182 (0.0300.470) 0.681 (0.0772.446) 0.059 (0.0000.336) 0.323 (0.0260.910)
Control group 1.294 (0.5103.779) 0.209 (0.0570.485) 0.977 (0.1833.285) 0.039 (0.0000.102) 0.275 (0.1020.534)
P 0.261 0.501 0.244 0.416 0.519
6th(N=165) Sorafenib group 1.273 (0.3982.823) 0.257 (0.1050.674) 0.863 (0.2022.633) 0.082 (0.0020.307) 0.272 (0.0950.595)
Control group 1.228 (0.3222.925) 0.232 (0.1050.347) 0.907 (0.1222.500) 0.076 (0.0070.226) 0.246 (0.0980.529)
P 0.858 0.824 0.587 0.557 0.842
9th(N=152) Sorafenib group 1.394 (0.2113.714) 0.211 (0.0580.458) 1.075 (0.1153.486) 0.111 (0.0010.344) 0.281 (0.0251.069)
Control group 1.236 (0.3563.702) 0.234 (0.0550.546) 0.899 (0.2093.159) 0.137 (0.0020.478) 0.309 (0.0520.903)
P 0.542 0.575 0.469 0.442 0.747
12th(N=141) Sorafenib group 1.626 (0.3093.906) 0.293 (0.0660.743) 1.220 (0.2223.630) 0.184 (0.0020.558) 0.271 (0.0100.755)
Control group 1.448 (0.5362.735) 0.315 (0.1020.764) 1.025 (0.3332.494) 0.229 (0.0031.208) 0.370 (0.0581.075)
P 0.459 0.627 0.410 0.448 0.141